Anti-Mouse CD8 Antibody (HB-129) is a mouse-derived inhibitory antibody that can specifically target mouse CD8 molecules and deplete CD8 T cells, and is mainly applicable to research in fields such as cancer, inflammation, immunology, and metabolic diseases.

Trivalent GalNAc-DBCO is a synthetic ligand composed of three GalNAc units linked to DBCO. Trivalent GalNAc-DBCO undergoes strain-promoted alkyne–azide cycloaddition (SPAAC) reactions with azide-containing molecules without the need for copper catalysis. Trivalent GalNAc-DBCO binds specifically to the asialoglycoprotein receptor (ASGPR), thereby directing conjugated molecules into hepatocytes for lysosomal degradation through receptor-mediated endocytosis. Trivalent GalNAc-DBCO is extensively applied in studies of liver-targeted drug delivery, targeted degradation strategies, and hepatocyte-specific molecular engineering.

WSF1-IN-1 is an orally bioavailable small-molecule inhibitor of the WSF1 protein, designed for the investigation of WSF1-associated tumorigenesis in Wolfram syndrome. in studies using HepG2 parental and HepG2 WFS1 knockout cell lines, WSF1-IN-1 demonstrated differential inhibitory potency with IC50 values of 0.33 μM, confirming its target selectivity and mechanistic specificity in modulating WSF1-related cellular pathways.

Anti-AGER/RAGE Antibody (XT-M4) is a humanized antibody expressed in CHO cells that specifically targets AGER/RAGE.

Anti-Mouse ICOSL/CD275 Antibody (HK5.3) is a monoclonal antibody against mouse ICOSL/CD275. It inhibits the adhesion between T cells and endothelial cells, reduces the expansion of TR Treg cells, and is suitable for studies on inflammatory and infectious diseases such as influenza virus infection and arthritis.